An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2004
This article has no abstract
Epistemonikos ID: 5719ecf43f6eadc79da10fc04f732543249def37
First added on: Jan 21, 2025